SWISS BIOTECH DAY 2023

Media Conference

April 24, 2023, Congress Center Basel, Room Rio
Swiss Biotech Report 2023

Frederik Schmachtenberg, Michael Altorfer
April 24, 2023
Sector weathers global disruption well & continues to drive healthcare innovation

- Record revenues of CHF 6.8B
- Industry’s CHF 1.3B fund raising exceeds 2019 pre-COVID levels
- R&D investment reaches new record of CHF 2.7B
- 47 approvals by Swissmedic – a record
- Employment grows 7.2% - talent pool broadens
- Ecosystem strengthens, ~20% of European biotech companies now headquartered in Switzerland
- Swiss Biotech Association celebrates 25 years of Swiss biotech innovation
The year in figures

The 2022 data in the presented tables is based on information that was available up until March 31, 2023, when this report was compiled and went to press. At this time, some of the companies had not yet disclosed their financial figures for 2022. Therefore, some figures were carefully extrapolated on the basis of the latest interim data publicly available (i.e., Q3 or Q4 2022).
Capital investments in Swiss biotech companies 2012-2022
Private and public Swiss biotech companies

Source: EY (Capital investments include convertible bonds)
Swiss biotech companies raised a total of CHF 1.3B in 2022
Largest public and private financing rounds

### 2022 public financing rounds

<table>
<thead>
<tr>
<th>PUBLIC COMPANIES</th>
<th>CHF MILLION</th>
</tr>
</thead>
<tbody>
<tr>
<td>VectivBio Holding</td>
<td>177</td>
</tr>
<tr>
<td>ADC Therapeutics</td>
<td>166</td>
</tr>
<tr>
<td>MoonLake Immunotherapeutics</td>
<td>140</td>
</tr>
<tr>
<td>Basilea</td>
<td>75</td>
</tr>
<tr>
<td>BioCartis</td>
<td>65</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>623</strong></td>
</tr>
</tbody>
</table>

### 2022 private financing rounds

<table>
<thead>
<tr>
<th>PRIVATE COMPANIES</th>
<th>CHF MILLION</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDR-Life</td>
<td>72</td>
</tr>
<tr>
<td>ImmunOS Therapeutics</td>
<td>71</td>
</tr>
<tr>
<td>Cimeio Therapeutics</td>
<td>46</td>
</tr>
<tr>
<td>Opna Bio</td>
<td>36</td>
</tr>
<tr>
<td>Anokion</td>
<td>35</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>260</strong></td>
</tr>
</tbody>
</table>

Source: Annual Reports, website information, EY
Biotech financing categories in Switzerland 2012-2022

Source: Annual Reports, website information, EY
Public and private Swiss regional financing 2020-2022

Source: Annual Reports, website information, EY
Note: The 2022 data in above tables is based on information that was available up until March 31, 2023. At this time, some of the companies had not yet disclosed their financial figures for 2022. Therefore, some figures were carefully extrapolated on the basis of the latest interim data publicly available (i.e. Q3 or Q4 2022).
Number of biotech companies in Switzerland 2013-2022

Source: Swiss Biotech Association, website information, EY
Number of employees in Swiss R&D biotech companies 2020-2022

Source: Annual Reports, website information and EY
Life science exports CHF CHF 109.6B, up from 109.0B in 2021
Pharma and biotech represent 39% of Swiss exports
Life science exports: Steady growth across two decades
Pharma and biotech exports increased by 255% over the last 20 years

Life science sector’s contribution to exports has grown by 255% since 2002, making it the strongest single driver of Swiss export growth
Swiss Biotech Report 2023
Effective solutions for global challenges
Swiss Biotech Report 2023
Effective solutions for global challenges

• 25 years of achievements, future pipeline strong
• Swiss biotech industry focused on global medical needs
• Government support focused on academic research and talent formation
• Biotech patents: Switzerland continues to hold a leading position with world-class and high impact patents and often develops these in international collaborations
• New topics of precision medicine, blockchain, AI & sustainability being embraced
• R&D investments at record level despite more difficult funding environment
• Sparks segment of SIX Swiss Exchange supports innovative SMEs
• All backed by broad talent pool, strong infrastructure and supportive environment
Impactful patents developed in international collaboration

Figure 1: Portfolio size of Swiss origin biotech patents by ownership type (2000 to 2022)

Figure 2: Average Competitive Impact™ of Swiss origin biotech patents by ownership type (data for the reporting date December 31, 2022)

Source: IGE/IPI, Swiss Biotech Report 2023
Co-inventor countries of Swiss biotech patents

Figure 3: Overview of co-inventor countries listed in Swiss biotech patents and their average Competitive Impact™ (data for the reporting date December 31, 2022)

Percentage of Swiss biotech patents with co-inventors from respective countries

- Germany: 31%
- USA: 30%
- France: 16%
- United Kingdom: 8%
- Italy: 6%
- Netherlands: 4%
- China: 4%
- Austria: 3%
- Denmark: 3%
- Belgium: 3%
- Canada: 3%
- Sweden: 2%
- Australia: 2%
- Costa Rica: 2%
- Spain: 2%
- India: 2%
- Japan: 1%
- South Korea: 1%
- Israel: 1%
- Poland: 1%

Source: IGE/IPI, Swiss Biotech Report 2023
Top 20 countries of biotech patents' origin

Source: IGE/IPI, Swiss Biotech Report 2023
Celebrating 25 years of the Swiss Biotech Association
Major achievements of Swiss biotech innovation

Most of these highlights were achieved in international collaboration and benefit patients around the world. They do not represent a comprehensive list but rather a selection that emphasizes the diversity of modalities that have been developed over time and the broad range of medical needs they help to address. Supported by Citeline.
Swiss biotech companies are progressing and succeeding along the ‘Commercialization Journey’

- **~20%**
  - Is the proportion of European biotech companies that are headquartered in Switzerland, representing >90 companies in 2022²

- **~7%**
  - The proportion of all innovative medicines launched in Europe were developed by Swiss biotech companies in the past 5 years⁴

- **$276 million**
  - Revenue (at list prices) generated by Swiss biotech companies in Europe in the past 5 years⁷

- **191**
  - Molecules with active clinical trials lead by >90 companies with Swiss HQs in 2022®

- **+25% higher**
  - Rate of availability in European markets for medicines developed by Swiss biotech companies versus average biotech launches in the past 5 years⁵

---

IQVIA analysis 2022, using MIDAS Q1 2022 sales data, for all references, see IQVIA guest article in the Swiss Biotech Report 2023
Modality and therapeutic area hotspots in Europe

<table>
<thead>
<tr>
<th>Modality hotspots</th>
<th>Therapeutic area hotspots</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Services</strong>³</td>
<td><strong>Oncology</strong></td>
</tr>
<tr>
<td><strong>CGT</strong></td>
<td><strong>CNS</strong></td>
</tr>
<tr>
<td>**Immuno-</td>
<td>(<strong>Other (examples)</strong></td>
</tr>
<tr>
<td>therapies**</td>
<td></td>
</tr>
<tr>
<td><strong>Antibodies</strong></td>
<td><strong>Dermatology</strong></td>
</tr>
<tr>
<td>**Leading</td>
<td>**Other e.g.</td>
</tr>
<tr>
<td>centers¹</td>
<td>Cardiovascular and</td>
</tr>
<tr>
<td></td>
<td>Ophthalmology**</td>
</tr>
<tr>
<td><strong>Growth centers²</strong></td>
<td>**Gastrointestinal/</td>
</tr>
<tr>
<td></td>
<td>Metabolic Diseases**</td>
</tr>
</tbody>
</table>

1. Top 3 European countries in terms of number of companies in Therapeutic area or Modality
2. Countries with largest growth in absolute number of companies since 2015 (which are not a leading center today)
3. Drug discovery tools & services, and diagnostic & personalized care solutions

Source: BCGQ (February 2021); McKinsey BVHOMA (2021)

DOCUMENT INTENDED TO PROVIDE INSIGHT BASED ON CURRENTLY AVAILABLE INFORMATION FOR CONSIDERATION AND NOT SPECIFIC ADVICE
Biotechnology applications beyond healthcare

• Global sales of biotechnology sector amount to USD 500B, ~50% relate to healthcare applications

• Huge potential for biotechnology applications beyond healthcare

• The Swiss Biotech Association launches separate chapter to develop an industrial biotech cluster in Switzerland

• Biotechnology is an innovation driver in major industries such as mining, construction, recycling and energy
The Swiss Biotech Association's Swiss Biotech Success Stories celebrate those who have made significant contributions to the industry.

Dedicated to scientists, pioneers, entrepreneurs, innovators and supporters who led the way, opened the horizon and prepared the ground for lasting achievements.

Awarded annually, the Swiss Biotech Success Stories accentuate past industry highlights and act as motivator for future achievements.
Swiss Biotech Success Stories award winners 2023

HUMABS BioMed
a subsidiary of Vir Biotechnology

SOPHIA GENETICS™

SWISS BIOTECH SUCCESS STORIES
Celebrating and honoring major achievements
Swiss Biotech Report 2023 - key figures 2022 at a glance

**REVENUES**
CHF 6.8 billion
Biotech sales in 2022

**EXPORTS**
CHF 110 billion
Exports of pharmaceuticals, vitamins and diagnostics

**BIOTECH COMPANIES**
354
R&D biotech companies

**NEW FUNDS**
CHF 1.3 billion
For private and public biotech

**RECORD R&D INVESTMENTS**
CHF 2.7 billion
R&D spending by biotech companies

**EMPLOYEES**
7,778 PRIVATE
in R&D biotech companies
11,354 PUBLIC

**APPROVALS**
37 FDA (50 in 2021)
89 EMA (91 in 2021)
47 Swissmedic (45 in 2021)
2021 regulatory approvals

**PATENTS**
#1 in Global Innovation Index
Top ranking in GII every year since 2011

**LIFE SCIENCES INDEX**
+2% SIX
5-year performance of SII Bio+Medtech (Jan 2018 - Dec 2022)

April 24, 2023